Acadia Pharmaceuticals, Inc. (ACAD) Reports In-Line Q4 Loss
Tweet Send to a FriendGet Alerts ACAD Hot Sheet
Price: $14.04 +1.81%
Revenue Growth %: -7.3%
Financial Fact:
Total operating expenses: 6.58M
Today's EPS Names:
DSX, REDF, REX, More
Revenue Growth %: -7.3%
Financial Fact:
Total operating expenses: 6.58M
Today's EPS Names:
DSX, REDF, REX, More
Trade ACAD Now!
Acadia Pharmaceuticals, Inc. (NASDAQ: ACAD) reported Q4 EPS of ($0.10), in-line with the analyst estimate of ($0.10). Revenue for the quarter came in at $588 thousand versus the consensus estimate of $550 thousand.
For earnings history and earnings-related data on Acadia Pharmaceuticals, Inc. (ACAD) click here.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
For earnings history and earnings-related data on Acadia Pharmaceuticals, Inc. (ACAD) click here.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- NetApp (NTAP) Tops Q4 EPS by 1c; Boosts Buyback, Plans Job Cuts, Initiates Dividend
- Target Corp. (TGT) Misses Q1 Views, Issues Mixed Outlook
- Lowes Cos. (LOW) Misses Q1 EPS by 2c; Reaffirms FY13 Outlook
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
